💊 Antidepressant Discontinuation Syndrome Simulator

Stable Antidepressant Dosing at Steady State

Drug concentration steady, receptors adapted, symptoms controlled well.

• 100%: Steady-state drug level (daily dosing equilibrium)
• 4–6 wks: Adaptation time (receptor downregulation)
• 0/10: Baseline symptom score (no discontinuation signs)
• SSRI/SNRI: Common classes (serotonergic maintenance)

Steady-state pharmacology

Daily dosing keeps plasma levels flat; receptors adapt over weeks.

Why stability matters

Stable levels prevent withdrawal-like symptoms while treatment continues.

Choosing How to Stop — Abrupt vs Tapered

Two paths diverge here: quit now, or step down slowly.

• 2: Paths compared (abrupt vs gradual taper)
• Taper: Recommended approach (per clinical guidelines)
• 4+ wks: Typical taper length (dose-dependent)
• Half-life: Risk driver (shorter = higher risk)

Why the choice matters

Stopping method strongly shapes symptom severity and duration.

Half-life factor

Short half-life drugs need slower, more careful tapering.

Sudden Stop — Rapid Drug Clearance and Symptom Spike

Levels crash fast; brain zaps and dizziness appear within days.

• ~4 days: Drug clearance (short half-life example)
• 1–3 days: Symptom onset (after last dose)
• ~day 4: Peak severity (score up to 9/10)
• Zaps, flu: Common signs (dizziness, irritability)

The cliff drop

Plasma concentration collapses quickly, straining adapted receptors.

Symptom cascade

Brain zaps, vertigo, irritability, and flu-like malaise emerge fast.

Stepwise Reduction — Smooth Decline, Minimal Symptoms

Small weekly dose cuts let receptors readjust gradually.

• 25%/wk: Taper schedule (stepwise dose reduction)
• ≤2/10: Symptom peak (per step, brief)
• 4 wks: Total duration (to full discontinuation)
• Lower: Relapse risk (vs abrupt stop)

Staircase decline

Each step gives receptors time to adapt before the next cut.

Minimal symptom load

Small transient bumps replace one large withdrawal spike.

Comparing Abrupt and Tapered Discontinuation Outcomes

Same drug, same patient, very different symptom trajectories.

• ~9/10: Abrupt peak severity (vs ~2/10 tapered)
• ~3 wks: Abrupt symptom duration (vs brief step bumps)
• Paroxetine: Highest-risk drugs (venlafaxine, short half-life)
• Slow taper: Best practice (clinician-guided schedule)

Severity and duration

Abrupt stop produces a sharp spike; taper stays flat and mild.

Drug half-life matters most

Short half-life drugs like paroxetine and venlafaxine hit hardest.